Patents by Inventor Masami Okabe
Masami Okabe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11965180Abstract: Provided is a cancer stem cell mass from which cells incapable of forming cancer are substantially removed and which has a characteristic property of reproducing a layered structure of a cancer tissue; a process for producing the cancer stem cell mass; and use of the cancer stem cell mass. A human cancer tissue was repeatedly grown in a NOG mouse, separated cancer cells from the grown cancer tissue, and tested and compared various cancer cell culture processes. As a result, a cancer stem cell composition which is homogeneous and is substantially free of the coexistence of cells capable of forming cancer and cells incapable of forming cancer in a mixed state can be produced successively by employing an attached culture process using a serum-free stem cell culture medium rather than a generally employed floating culture process.Type: GrantFiled: August 14, 2020Date of Patent: April 23, 2024Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Yu Jau Chen, Atsuhiko Kato, Masami Suzuki, Koichi Matsubara
-
Patent number: 11959398Abstract: This composite material blade, which is formed using a composite material including reinforcing fibers and resin, and which has a positive pressure surface and a negative pressure surface, is provided with a ventral part, being the part on the positive pressure surface side in a blade thickness direction, which is the direction joining the positive pressure surface and the negative pressure surface, a dorsal part, being the part on the negative pressure surface side in the blade thickness direction, and a metal shield portion which is provided on the leading edge side, being the upstream side in a flow direction in which a fluid flows, wherein: the metal shield portion includes a main body portion provided on the leading edge side, and an embedded portion which is provided on the trailing edge side, being the downstream side in the flow direction, of the main body portion, and which is provided between the ventral part and the dorsal part; and the plate thickness of the metal shield portion in the blade thickType: GrantFiled: February 22, 2021Date of Patent: April 16, 2024Assignee: MITSUBISHI HEAVY INDUSTRIES, LTD.Inventors: Masami Kamiya, Ryoji Okabe, Kentaro Shindo, Takahiro Tachibana
-
Patent number: 10563208Abstract: The object of the invention is to provide an anaerobic enterobacterium having a higher therapeutic effect on an anaerobic site such as a solid tumor tissue and an ischemic disease site. A bacterium of the genus Bifidobacterium, which is transformed with a plasmid co-expressing two types of heterologous polypeptides and comprising two types of secretory expression cassettes each sequentially comprising a promoter DNA functioning in the bacterium of the genus Bifidobacterium; a DNA encoding a secretory signal peptide; a DNA encoding a heterologous polypeptide; and a terminator DNA functioning in the bacterium of the genus Bifidobacterium, efficiently secretes the two types of heterologous peptides, i.e., two types of antibodies having anticancer effects, outside the bacterial cell.Type: GrantFiled: December 2, 2015Date of Patent: February 18, 2020Assignee: Anaeropharma Science, Inc.Inventors: Koichi Koseki, Koichiro Shioya, Satoshi Kobayashi, Yuko Shimatani, Takeshi Masaki, Hitomi Shimizu, Tomio Matsumura, Masami Okabe, Kengo Inoue
-
Publication number: 20170260534Abstract: The object of the invention is to provide an anaerobic enterobacterium having a higher therapeutic effect on an anaerobic site such as a solid tumor tissue and an ischemic disease site. A bacterium of the genus Bifidobacterium, which is transformed with a plasmid co-expressing two types of heterologous polypeptides and comprising two types of secretory expression cassettes each sequentially comprising a promoter DNA functioning in the bacterium of the genus Bifidobacterium; a DNA encoding a secretory signal peptide; a DNA encoding a heterologous polypeptide; and a terminator DNA functioning in the bacterium of the genus Bifidobacterium, efficiently secretes the two types of heterologous peptides, i.e., two types of antibodies having anticancer effects, outside the bacterial cell.Type: ApplicationFiled: December 2, 2015Publication date: September 14, 2017Inventors: Koichi KOSEKI, Koichiro SHIOYA, Satoshi KOBAYASHI, Yuko SHIMATANI, Takeshi MASAKI, Hitomi SHIMIZU, Tomio MATSUMURA, Masami OKABE, Kengo INOUE
-
Patent number: 7592311Abstract: The invention relates to a polypeptide wherein at least one of the amino, carboxyl, mercapto or guanidino group in a polypeptide molecule having human granulocyte colony stimulating factor activity is chemically modified by a chemical modifying agent, and a platelet production promoter comprising said polypeptide, a method for treating a patient with decreased platelet counts comprising administering an effective amount of said polypeptide to the patient, the use of said polypeptide for the production of pharmaceutical compositions which are useful for the treatment of the patient with decreased platelet counts, and the compositions for treating the patient with decreased platelet counts, which comprises an effective dose of said polypeptide in a pharmaceutically acceptable dosage form with a pharmaceutical acceptable carrier.Type: GrantFiled: October 20, 2005Date of Patent: September 22, 2009Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Motoo Yamasaki, Masami Okabe, Toshiyuki Suzawa, Ken Kobayashi, Kumiko Maruyama
-
Publication number: 20060040865Abstract: The invention relates to a polypeptide wherein at least one of the amino, carboxyl, mercapto or guanidino group in a polypeptide molecule having human granulocyte colony stimulating factor activity is chemically modified by a chemical modifying agent, and a platelet production promoter comprising said polypeptide, a method for treating a patient with decreased platelet counts comprising administering an effective amount of said polypeptide to the patient, the use of said polypeptide for the production of pharmaceutical compositions which are useful for the treatment of the patient with decreased platelet counts, and the compositions for treating the patient with decreased platelet counts, which comprises an effective dose of said polypeptide in a pharmaceutically acceptable dosage form with a pharmaceutical acceptable carrier.Type: ApplicationFiled: October 20, 2005Publication date: February 23, 2006Inventors: Motoo Yamasaki, Masami Okabe, Toshiyuki Suzawa, Ken Kobayashi, Kumiko Maruyama
-
Patent number: 6353123Abstract: A stereospecific method for accomplishing the below reaction: results in the compound of formula 2 having the same stereochemistry at both carbon 1 and carbon 3 as that in the compound of formula 1. Thus, if carbon 3 is in the R-configuration in the compound of formula 1, then carbon 3 will be in the R-configuration in the compound of resulting formula 2. In the above process, R1 is C1-C6 alkyl that can be straight-chain or branched. The process functions using a fluorinated alcohol having a pKa less than about 9, in the presence of a palladium catalyst. The compounds of formula 1, as well as novel intermediates in this process, are useful in manufacturing vitamin D analogs.Type: GrantFiled: April 16, 2001Date of Patent: March 5, 2002Assignee: Hoffmann-La Roche Inc.Inventors: Andrzej Robert Daniewski, Marek Michal Kabat, Masami Okabe, Roumen Nikolaev Radinov
-
Patent number: 6294688Abstract: A stereospecific method for accomplishing the below reaction: results in the compound of formula 2 having the same stereochemistry at both carbon 1 and carbon 3 as that in the compound of formula 1. Thus, if carbon 3 is in the R-configuration in the compound of formula 1, then carbon 3 will be in the R-configuration in the compound of resulting formula 2. In the above process, R1 is C1-C6 alkyl that can be straight-chain or branched. The process functions using a fluorinated alcohol having a pKa less than about 9, in the presence of a palladium catalyst. The compounds of formula 1, as well as novel intermediates in this process, are useful in manufacturing vitamin D analogs.Type: GrantFiled: August 7, 2000Date of Patent: September 25, 2001Assignee: Hoffman-La Roche Inc.Inventors: Andrzej Robert Daniewski, Marek Michal Kabat, Masami Okabe, Roumen Nikolaev Radinov
-
Patent number: 6291694Abstract: A stereospecific method for accomplishing the below reaction: results in the compound of formula 2 having the same stereochemistry at both carbon 1 and carbon 3 as that in the compound of formula 1. Thus, if carbon 3 is in the R-configuration in the compound of formula 1, then carbon 3 will be in the R-configuration in the compound of resulting formula 2. In the above process, R1 is C1-C6 alkyl that can be straight-chain or branched. The process functions using a fluorinated alcohol having a pKa less than about 9, in the presence of a palladium catalyst. The compounds of formula 1, as well as novel intermediates in this process, are useful in manufacturing vitamin D analogs.Type: GrantFiled: August 7, 2000Date of Patent: September 18, 2001Assignee: Hoffman-La Roche Inc.Inventors: Andrzej Robert Daniewski, Marek Michal Kabat, Masami Okabe, Roumen Nikolaev Radinov
-
Patent number: 6245900Abstract: The invention relates to a polypeptide wherein at least one of the amino, carboxyl, mercapto or guanidino group in a polypeptide molecule having human granulocyte colony stimulating factor activity is chemically modified by a chemical modifying agent, and a platelet production promoter comprising said polypeptide, a method for treating a patient with decreased platelet counts comprising administering an effective amount of said polypeptide to the patient, the use of said polypeptide for the production of pharmaceutical compositions which are useful for the treatment of the patient with decreased platelet counts, and the compositions for treating the patient with decreased platelet counts, which comprises an effective dose of said polypeptide in a pharmaceutically acceptable dosage form with a pharmaceutical acceptable carrier.Type: GrantFiled: August 16, 1996Date of Patent: June 12, 2001Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Motoo Yamasaki, Masami Okabe, Toshiyuki Suzawa, Ken Kobayashi, Kumiko Maruyama
-
Patent number: 6027720Abstract: Novel hG-CSF polypeptide derivatives having an amino acid sequence derived from the amino acid sequence of the human granulocyte colony stimulating factor polypeptide by substitution of at least one amino acid by a different amino acid and/or deletion of at least one amino acid, recombinant plasmids containing a DNA fragment insert coding for any of these hG-CSF polypeptide derivatives, microorganisms carrying one of such plasmids, methods of producing the hG-CSF polypeptide derivatives using the microorganisms, a monoclonal antibody binding to the hG-CSF polypeptide derivative, and chemically modified hG-CSF or derivatives thereof are disclosed.Type: GrantFiled: July 13, 1994Date of Patent: February 22, 2000Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Tetsuro Kuga, Hiromasa Miyaji, Moriyuki Sato, Masami Okabe, Makoto Morimoto, Seiga Itoh, Motoo Yamasaki, Yoshiharu Yokoo, Kazuo Yamaguchi, Hajime Yoshida, Yoshinori Komatsu
-
Patent number: 5994518Abstract: Novel hG-CSF polypeptide derivatives having an amino acid sequence derived from the amino acid sequence of the human granulocyte colony stimulating factor polypeptide by substitution of at least one amino acid by a different amino acid and/or deletion of at least one amino acid, recombinant plasmids containing a DNA fragment insert coding for any of these hG-CSF polypeptide derivatives, microorganisms carrying one of such plasmids, methods of producing the hG-CSF polypeptide derivatives using the microorganisms, a monoclonal antibody binding to the hG-CSF polypeptide derivative, and chemically modified hG-CSF or derivatives thereof are disclosed.Type: GrantFiled: July 9, 1997Date of Patent: November 30, 1999Assignee: Kyowa Hakko Co., LtdInventors: Tetsuro Kuga, Hiromasa Miyaji, Moriyuki Sato, Masami Okabe, Makoto Morimoto, Seiga Itoh, Motoo Yamasaki, Yoshiharu Yokoo, Kazuo Yamaguchi, Hajime Yoshida, Yoshinori Komatsu
-
Patent number: 5952355Abstract: The present invention relates to propenone derivatives represented by the following formula (I): ##STR1## wherein R.sup.1 represents hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, or YR.sup.5 (wherein Y represents S or O; and R.sup.5 represents substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or a substituted or unsubstituted cyclic ether residue); R.sup.2 and R.sup.3 independently represent hydrogen, lower alkyl, or substituted or unsubstituted aralkyl, or alternatively R.sup.2 and R.sup.3 are combined to form substituted or unsubstituted methylene or ethylene; R.sup.4 represents hydrogen, hydroxy, lower alkyl, substituted or unsubstituted aralkyl, lower alkoxy, substituted or unsubstituted aralkyloxy, or halogen; and X represents substituted or unsubstituted indolyl; or pharmaceutically acceptable salts thereof.Type: GrantFiled: November 26, 1996Date of Patent: September 14, 1999Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Shun-Ichi Ikeda, Uichiro Kimura, Tadashi Ashizawa, Katsushige Gomi, Hiromitsu Saito, Masaji Kasai, Junji Kanazawa, Kimihito Sasaki, Etsuko Nukui, Masami Okabe, Soichiro Sato
-
Patent number: 5885830Abstract: An anti-ribonucleotide reductase (RNR) R2 subunit monoclonal antibody KM1054, KM1056 or KM1060, which belongs to the IgG2a subclass, reacts with R2 subunit of RNR, and inhibits RNR activity, is disclosed. It is effective for immunologically detecting RNR and for immunologically detecting the presence of human cancer cells.Type: GrantFiled: February 7, 1996Date of Patent: March 23, 1999Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Toshiaki Saeki, Toshiaki Kamei, Akiko Furuya, Nobuo Hanai, Takeshi Takahashi, Masami Okabe, Motoo Yamasaki
-
Patent number: 5795968Abstract: Novel hG-CSF polypeptide derivatives having an amino acid sequence derived from the amino acid sequence of the human granulocyte colony stimulating factor polypeptide by substitution of at least one amino acid by a different amino acid and/or deletion of at least one amino acid, recombinant plasmids containing a DNA fragment insert coding for any of these hG-CSF polypeptide derivatives, microorganisms carrying one of such plasmids, methods of producing the hG-CSF polypeptide derivatives using the microorganisms, a monoclonal antibody binding to the hG-CSF polypeptide derivative, and chemically modified hG-CSF or derivatives thereof are disclosed.Type: GrantFiled: January 10, 1997Date of Patent: August 18, 1998Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Tetsuro Kuga, Hiromasa Miyaji, Moriyuki Sato, Masami Okabe, Makoto Morimoto, Seiga Itoh, Motoo Yamasaki, Yoshiharu Yokoo, Kazuo Yamaguchi, Hajime Yoshida, Yoshinori Komatsu
-
Patent number: 5789607Abstract: A process for preparing 1,25-dihydroxy-16-ene-23-yne cholecalciferol.Type: GrantFiled: April 18, 1997Date of Patent: August 4, 1998Assignee: Hoffmann-La Roche Inc.Inventor: Masami Okabe
-
Patent number: 5714581Abstract: Novel hG-CSF polypeptide derivatives having an amino acid sequence derived from the amino acid sequence of the human granulocyte colony stimulating factor polypeptide by substitution of at least one amino acid by a different amino acid and/or deletion of at least one amino acid, recombinant plasmids containing a DNA fragment insert coding for any of these hG-CSF polypeptide derivatives, microorganisms carrying one of such plasmids, methods of producing the hG-CSF polypeptide derivatives using the microorganisms, a monoclonal antibody binding to the hG-CSF polypeptide derivative, and chemically modified hG-CSF or derivatives thereof are disclosed.Type: GrantFiled: May 3, 1995Date of Patent: February 3, 1998Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Tetsuro Kuga, Hiromasa Miyaji, Moriyuki Sato, Masami Okabe, Makoto Morimoto, Seiga Itoh, Motoo Yamasaki, Yoshiharu Yokoo, Kazuo Yamaguchi, Hajime Yoshida, Yoshinori Komatsu
-
Patent number: 5681720Abstract: Novel hG-CSF polypeptide derivatives having an amino acid sequence derived from the amino acid sequence of the human granulocyte colony stimulating factor polypeptide by substitution of at least one amino acid by a different amino acid and/or deletion of at least one amino acid, recombinant plasmids containing a DNA fragment insert coding for any of these hG-CSF polypeptide derivatives, microorganisms carrying one of such plasmids, methods of producing the hG-CSF polypeptide derivatives using the microorganisms, a monoclonal antibody binding to the hG-CSF polypeptide derivative, and chemically modified hG-CSF or derivatives thereof are disclosed.Type: GrantFiled: May 3, 1995Date of Patent: October 28, 1997Assignee: Kyowa Hakko Co., Ltd.Inventors: Tetsuro Kuga, Hiromasa Miyaji, Moriyuki Sato, Masami Okabe, Makoto Morimoto, Seiga Itoh, Motoo Yamasaki, Yoshiharu Yokoo, Kazuo Yamaguchi, Hajime Yoshida, Yoshinori Komatsu
-
Patent number: 5674867Abstract: The present invention relates to therapeutic agents for thrombocytopenia which contain an indolocarbazole derivative represented by the formula (I) given below or a pharmaceutically acceptable salt thereof as an active ingredient, and to novel indolocarbazole derivatives.Type: GrantFiled: May 18, 1994Date of Patent: October 7, 1997Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Tatsuya Tamaoki, Yukimasa Shiotsu, Chikara Murakata, Shiro Akinaga, Masami Okabe, Yutaka Saito, Junichi Watanabe, Takako Shiraki
-
Patent number: 5629304Abstract: The present invention provides a method of treating thrombocytopenia, which comprises administering to a patient suffering from thrombocytopenia, an effective amount of an indolocarbazole derivative represented by formula (I): ##STR1## wherein R.sup.1 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted aralkyl group or a tetrahydropyranyl group; R.sup.2A and R.sup.3A, which may be the same or different, each represent a hydrogen atom, a substituted or unsubstituted lower alkyl group, a lower alkenyl group, a substituted or unsubstituted aralkyl group or a monosaccharide residue where a hydroxyl group at the anomer position is removed; R.sup.4A and R.sup.5A, which may be the same or different, each represent a hydrogen atom, a formyl group, a hydroxyl group or a halogen atom; W.sup.A1 and W.sup.A2 represent hydrogen atoms or are combined together to form an oxygen atom; and X.sup.A1 and X.sup.Type: GrantFiled: April 25, 1996Date of Patent: May 13, 1997Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Chikara Murakata, Fumihiko Kanai, Yutaka Saitoh, Yukimasa Shiotsu, Takako Shiraki, Tatsuya Tamaoki, Shiro Akinaga, Masami Okabe